Get the Stockscreener App
16.07
4.46%
-0.75
After Hours:
16.03
-0.04
-0.25%
Arrowhead Pharmaceuticals Inc stock is traded at $16.07, with a volume of 1.90M.
It is down -4.46% in the last 24 hours and up +19.30% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$16.82
Open:
$16.78
24h Volume:
1.90M
Relative Volume:
1.06
Market Cap:
$2.22B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-11.56
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
+6.21%
1M Performance:
+19.30%
6M Performance:
-38.26%
1Y Performance:
-29.46%
1-Day Range:
$15.68
$16.78
1-Week Range:
$15.22
$17.19
52-Week Range:
$9.57
$30.41
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
16.07 | 2.09B | 181.74M | -143.97M | 9.60M | -1.39 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World
ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree
Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN
ARWR July 18th Options Begin Trading - Nasdaq
ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance
Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World
UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus
RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada
Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus
Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com Australia
Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours - marketscreener.com
Arrowhead Pharmaceuticals soars 7% on massive earnings beat By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals soars 7% on massive earnings beat - Investing.com Australia
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Rele - GuruFocus
Trend Tracker for (ARWR) - news.stocktradersdaily.com
Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Monday - Defense World
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer |
Apr 10 '25 |
Sale |
10.87 |
50,000 |
543,500 |
3,972,055 |
| Anzalone Christopher Richard | Chief Executive Officer |
Apr 09 '25 |
Sale |
10.07 |
40,322 |
406,145 |
4,022,055 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):